BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12
378 results:

  • 1. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
    Fu W; Feng Q; Tao R
    Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Association between inflammatory bowel disease and cancer risk: evidence triangulation from genetic correlation, Mendelian randomization, and colocalization analyses across East Asian and European populations.
    Liu D; Cao M; Wang H; Cao W; Zheng C; Li Y; Wang Y
    BMC Med; 2024 Mar; 22(1):137. PubMed ID: 38528540
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Linear IgA bullous dermatosis associated with immunotherapy.
    Momin B; Nguyen TF; Glade D; Messer A
    Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Machine learning developed a CD8
    Chen R; Zheng Y; Fei C; Ye J; Fei H
    Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer.
    Cui Y; Zhang W; Lu W; Feng Y; Wu X; Zhuo Z; Zhang D; Zhang Y
    Front Immunol; 2024; 15():1228235. PubMed ID: 38404588
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. CD133, CD47, and PD-L1 Expression in ovarian High-grade Serous Carcinoma and Its Association with Metastatic Disease: A Cross-sectional Study.
    Masadah R; Ikram D; Riadi R; Tangdiung Y; Nelwan BJ; Ghaznawie M; Rauf S; Faruk M
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):249-255. PubMed ID: 38285791
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
    Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
    Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Prognostic and immune infiltration features of disulfidptosis-related subtypes in breast cancer.
    Chen S; Li X; Ao W
    BMC Womens Health; 2024 Jan; 24(1):6. PubMed ID: 38166898
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
    Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
    Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
    [No Abstract]    [Full Text] [Related]  

  • 10. ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of ovarian cancer Screening (UKCTOCS).
    Dilley J; Gentry-Maharaj A; Ryan A; Burnell M; Manchanda R; Kalsi J; Singh N; Woolas R; Sharma A; Williamson K; Mould T; Fallowfield L; Campbell S; Skates SJ; McGuire A; Parmar M; Jacobs I; Menon U
    Gynecol Oncol; 2023 Dec; 179():123-130. PubMed ID: 37980767
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.
    Baumann KE; Siamakpour-Reihani S; Dottino J; Dai Y; Bentley R; Jiang C; Zhang D; Sibley AB; Zhou C; Berchuck A; Owzar K; Bae-Jump V; Secord AA
    Gynecol Oncol; 2023 Dec; 179():97-105. PubMed ID: 37956617
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Synthesis, characterization and multi-spectroscopic DNA/HSA interaction studies of synthetic human Follicle-Stimulating Hormone Beta 33-53 peptide conjugated PEGylated graphene oxide nanoparticles.
    Kalyani Bhardwaj B; Suresh PS
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Feb; 306():123552. PubMed ID: 37883823
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Machine Learning Developed a Programmed Cell Death Signature for Predicting Prognosis, Ecosystem, and Drug Sensitivity in ovarian cancer.
    Wang L; Chen X; Song L; Zou H
    Anal Cell Pathol (Amst); 2023; 2023():7365503. PubMed ID: 37868825
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
    Han X; Yang L; Tian H; Ji Y
    Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Establishment and validation of an immune infiltration predictive model for ovarian cancer.
    Song Z; Zhang J; Sun Y; Jiang Z; Liu X
    BMC Med Genomics; 2023 Sep; 16(1):227. PubMed ID: 37759229
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Bioinformatics analysis of the association between long non-coding RNA ubiquitin-specific peptidase 30 antisense RNA 1 (lncRNA USP30-AS1) and immune cell infiltration in ovarian serous cystadenocarcinoma].
    Wang H; Huang S; Meng Q; Zhang J; Wei L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Sep; 39(9):834-840. PubMed ID: 37732580
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer.
    Yang J; Wang C; Zhang Y; Cheng S; Xu Y; Wang Y
    J Ovarian Res; 2023 Sep; 16(1):196. PubMed ID: 37730669
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function.
    Funauchi M; Serada S; Hiramatsu K; Funajima E; Kanda M; Nagase Y; Nakagawa S; Ohkawara T; Fujimoto M; Suzuki Y; Ueda Y; Kimura T; Naka T
    Int J Cancer; 2024 Feb; 154(3):425-433. PubMed ID: 37728485
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Scoulerine promotes cytotoxicity and attenuates stemness in ovarian cancer by targeting PI3K/AKT/mTOR axis.
    Wang F; Zhang Y; Pang R; Shi S; Wang R
    Acta Pharm; 2023 Sep; 73(3):475-488. PubMed ID: 37708956
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
    Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
    J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 19.